Business Wire

Bacardi Shakes up Cocktails-at-Home With Launch of TAILS® COCKTAILS

30.3.2022 13:30:00 EEST | Business Wire | Press release

Share

Bacardi, the largest privately held spirits company in the world, is raising the bar for cocktails-at-home with the launch of TAILS COCKTAILS.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220330005116/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

BACARDI SHAKES UP COCKTAILS-AT-HOME WITH LAUNCH OF TAILS® COCKTAILS. (Photo: Business Wire)

This is the first time this new range of premium batched cocktails from TAILS will be available for consumers to enjoy at home. The brand was originally created for the hospitality industry, offering a hassle-free solution for serving premium quality cocktails easily, quickly and consistently.

“Over the last two years, cocktail awareness has boomed as people served up daiquiris, espresso martini cocktails and mojitos to make staying-in feel extra special,” said Evert-Jan Bos, General Manager of TAILS. “Now, as the on-trade reopens, consumers are enjoying the experience of being back in the bar and they’re ordering cocktails more than ever before.”

To tap into this thriving cocktail culture, TAILS is bringing a taste of the bar home with new-look packaging and new recipes. Made using the Bacardi portfolio of premium brands blended with top quality ingredients, the pre-batched cocktail range is perfectly positioned for the rise in entertaining at home, and an ever-growing demand for hyper-convenience. People can now enjoy the experience of shaking up a bar quality cocktail in just 30 seconds, with no planning required.

Evert-Jan adds: “This is a game-changer for the home bar. TAILS COCKTAILS offer both incredible taste and convenience, making it easier than ever for people to enjoy the same flavor and complexity of a cocktail made from scratch, without any effort or expertise. No shopping for ingredients, no measuring, no recipes - just add ice, shake and pour – how easy is that?”

There are five TAILS COCKTAILS - the ‘Rum Daiquirí’ made with BACARDÍ® rum; the ‘Whisky Sour’ with DEWAR’S® Blended Scotch whisky; the ‘Gin Gimlet’ with BOMBAY SAPPHIRE® gin; and the ‘Espresso Martini Cocktail’ and ‘Passion Fruit Martini Cocktail’, both made with 42BELOW® vodka.

Francis Debeuckelaere, Regional President, Western Europe, Australia & New Zealand, comments: “Of course you can never replace the experience of enjoying a favorite cocktail in a local bar, however we’re going one step further to offer more and more fantastic choices for consumers. With TAILS we’re delivering new experiences for the home, putting cocktails on the menu whatever the occasion. We are pioneering a whole new ‘ready-to-shake’ category.”

A QR code on every 50cl bottle links to a 30 second ‘how to’ video which explains the three simple serving steps, along with garnish suggestions, for each cocktail: 1, add ice and 125ml of the TAILS cocktail to a shaker; 2, experience that ‘bartender feeling’ by shaking until ice cold; and 3, pour into a glass.

TAILS will be available from April in supermarkets, specialist liquor stores and online across the UK & Ireland, Netherlands, Belgium, Germany, Austria, and Australia, supported by a digital-first marketing campaign focused on building awareness and driving trial of the new range.

For more information on TAILS COCKTAILS, visit www.tailscocktails.com.

Always drink responsibly.

About TAILS®

TAILS COCKTAILS is an exclusive range of premium pre-batched cocktails that bring the experience of the bar to consumers’ homes, with all the flavor and complexity of hand-made cocktails, but none of the effort. Established in 2010, TAILS was founded with a vision to make high-quality cocktails more accessible to a wider audience of cocktail lovers. Each TAILS COCKTAIL begins with the highest quality, premium spirits – BACARDI® Rum, 42BELOW® Vodka, BOMBAY SAPPHIRE® Gin and DEWAR’S® Blended Scotch whisky – blended with top quality ingredients. The TAILS brand is part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda.

Visit www.tailscocktails.com.

About Bacardi

Bacardi Limited, the largest privately held spirits company in the world, produces and markets internationally recognized spirits and wines. The Bacardi Limited brand portfolio comprises more than 200 brands and labels, including BACARDÍ® rum, GREY GOOSE® vodka, PATRÓN® tequila, DEWAR’S® Blended Scotch whisky, BOMBAY SAPPHIRE® gin, MARTINI® vermouth and sparkling wines, CAZADORES® 100% blue agave tequila, and other leading and emerging brands including WILLIAM LAWSON’S® Scotch whisky, ST-GERMAIN® elderflower liqueur, and ERISTOFF® vodka. Founded over 160 years ago in Santiago de Cuba, family-owned Bacardi Limited currently employs more than 8,000, operates production facilities in 10 countries, and sells its brands in more than 170 countries. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Visit http://www.bacardilimited.com or follow us on Twitter, LinkedIn or Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Phillippa Williams, Corporate Communications Manager, Western Europe, Australia & New Zealand, pholmes@bacardi.com
Andrew Carney, Corporate Communications Director, Western Europe, Australia & New Zealand, acarney@bacardi.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye